Compare Sun Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs NOVARTIS - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA NOVARTIS SUN PHARMA/
NOVARTIS
 
P/E (TTM) x 27.7 1,873.2 1.5% View Chart
P/BV x 2.8 24.9 11.3% View Chart
Dividend Yield % 0.6 1.8 32.1%  

Financials

 SUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
NOVARTIS
Mar-19
SUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs679980 69.3%   
Low Rs375600 62.5%   
Sales per share (Unadj.) Rs121.1198.7 61.0%  
Earnings per share (Unadj.) Rs13.421.0 63.8%  
Cash flow per share (Unadj.) Rs20.722.3 92.9%  
Dividends per share (Unadj.) Rs2.7510.00 27.5%  
Dividend yield (eoy) %0.51.3 41.2%  
Book value per share (Unadj.) Rs172.6307.5 56.1%  
Shares outstanding (eoy) m2,399.2624.69 9,717.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.0 109.4%   
Avg P/E ratio x39.437.7 104.6%  
P/CF ratio (eoy) x25.535.5 71.8%  
Price / Book Value ratio x3.12.6 118.9%  
Dividend payout %20.647.7 43.1%   
Avg Mkt Cap Rs m1,264,65019,508 6,482.9%   
No. of employees `00017.50.6 3,012.2%   
Total wages/salary Rs m59,6711,171 5,095.3%   
Avg. sales/employee Rs Th16,608.18,445.4 196.7%   
Avg. wages/employee Rs Th3,409.62,015.7 169.2%   
Avg. net profit/employee Rs Th1,833.8891.0 205.8%   
INCOME DATA
Net Sales Rs m290,6594,907 5,923.6%  
Other income Rs m10,255783 1,310.4%   
Total revenues Rs m300,9145,689 5,289.0%   
Gross profit Rs m63,076123 51,364.7%  
Depreciation Rs m17,53332 55,133.6%   
Interest Rs m5,55316 34,921.4%   
Profit before tax Rs m50,246858 5,858.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009340 1,767.3%   
Profit after tax Rs m32,093518 6,199.2%  
Gross profit margin %21.72.5 867.1%  
Effective tax rate %12.039.6 30.2%   
Net profit margin %11.010.6 104.7%  
BALANCE SHEET DATA
Current assets Rs m310,6928,055 3,857.4%   
Current liabilities Rs m173,3961,850 9,372.3%   
Net working cap to sales %47.2126.4 37.4%  
Current ratio x1.84.4 41.2%  
Inventory Days Days9945 220.0%  
Debtors Days Days11234 329.0%  
Net fixed assets Rs m232,477150 155,191.5%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m411,6917,469 5,512.4%   
Net worth Rs m414,0917,592 5,454.4%   
Long term debt Rs m15,2260-   
Total assets Rs m646,9389,824 6,585.0%  
Interest coverage x10.054.9 18.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 90.0%   
Return on assets %5.85.4 107.1%  
Return on equity %7.86.8 113.7%  
Return on capital %10.211.5 88.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02558 114,627.4%   
Fx outflow Rs m38,6101,326 2,911.1%   
Net fx Rs m27,415-1,269 -2,160.9%   
CASH FLOW
From Operations Rs m21,965-1,943 -1,130.6%  
From Investments Rs m-6,8132,742 -248.4%  
From Financial Activity Rs m-27,305-298 9,156.7%  
Net Cashflow Rs m-8,442501 -1,683.9%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 2.0 256.5%  
FIIs % 23.0 1.6 1,437.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.5 38.6%  
Shareholders   133,026 41,647 319.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   AUROBINDO PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 408 Points Higher; Banking and Metal Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest after a 1-day hiatus and ended on a strong note today.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 9, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - SHASUN PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS